Taken together the in vitro, in vivo and ex vivo validation studies, it was proven that Gonearrestide could inhibit the growth of primary colon cancer cells and solid tumours by triggering cell cycle arrest in G1 phase through inhibition of cyclin‐dependent kinases 4 (CDK4) and up‐regulate the expression of cell cycle regulators/inhibitors—cyclin D3, p27, and p21. Here, CDK4 is linked to malignant colon neoplasm.